Form 4: EyePoint Pharmaceuticals Director Transfers Over 230,000 Vested Stock Options to Family Trust
Insider Transaction Disclosure
EyePoint Pharmaceuticals Director Nancy Lurker transferred 232,021 vested stock options with various exercise prices to an irrevocable family trust on July 2, 2025, for estate planning purposes.
Summary
- Director Nancy Lurker of EyePoint Pharmaceuticals, Inc. transferred 232,021 vested stock options to an irrevocable family trust on July 2, 2025.
- The options transferred include:
- 31,165 options with an exercise price of $13.13, expiring February 9, 2031.
- 55,000 options with an exercise price of $10.13, expiring February 9, 2032.
- 103,308 options with an exercise price of $3.26, expiring January 5, 2033.
- 15,278 options with an exercise price of $9.11, expiring July 10, 2033.
- 27,270 options with an exercise price of $20.40, expiring January 4, 2034.
- The family trust's beneficiaries are the reporting person's immediate family members, and the reporting person's spouse is the trustee.
- The reporting person disclaims beneficial ownership of these transferred securities.
- Following the transaction, Nancy Lurker directly holds 302,894 stock options and indirectly holds 745,272 stock options through the Family Trust, totaling 1,048,166 options.
Sentiment
Score: 5
Explanation: The document reports a routine insider transaction (transfer of vested stock options to a family trust) for estate planning purposes. This type of transaction is generally neutral as it does not reflect a direct buy or sell decision based on company performance or outlook, but rather a personal financial management strategy.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This Form 4 filing is a routine disclosure of an insider's personal financial planning related to their equity compensation. It does not provide information on broader industry trends or competitive landscape.
Comparison to Industry Standards
- NA
Related Party Transactions
- The reporting person transferred vested stock options to an irrevocable family trust, where the reporting person's spouse is trustee and immediate family members are beneficiaries. This constitutes a related party transaction for estate planning purposes.
Stakeholder Impact
- Shareholders may note the director's long-term holding strategy for a significant portion of their equity compensation, albeit through a trust. There is no direct impact on employees, customers, suppliers, or creditors from this specific transaction.
Next Steps
- Remaining portions of certain stock options retained by the reporting person will continue to vest monthly until specific future dates (February 9, 2026; January 6, 2027; July 10, 2027; January 5, 2028).
Key Dates
| Date | Description |
|---|---|
| 2025-07-02 | Date of earliest transaction: transfer of vested stock options to an irrevocable family trust. |
| 2026-02-09 | Remaining portion of stock options with $13.13 and $10.13 exercise prices continue to vest until this date. |
| 2027-01-06 | Remaining portion of stock options with $3.26 exercise price continue to vest until this date. |
| 2027-07-10 | Remaining portion of stock options with $9.11 exercise price continue to vest until this date. |
| 2028-01-05 | Remaining portion of stock options with $20.40 exercise price continue to vest until this date. |
| 2031-02-09 | Expiration date for stock options with an exercise price of $13.13. |
| 2032-02-09 | Expiration date for stock options with an exercise price of $10.13. |
| 2033-01-05 | Expiration date for stock options with an exercise price of $3.26. |
| 2033-07-10 | Expiration date for stock options with an exercise price of $9.11. |
| 2034-01-04 | Expiration date for stock options with an exercise price of $20.40. |
Keywords
SEC Form 4, Insider Transaction, Stock Options, Beneficial Ownership, Family Trust, Estate Planning, EyePoint Pharmaceuticals, EYPT, Director Holdings, Derivative Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.